Skip to Main Content

Paper Details

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
NPJ Breast Cancer
14
2021
Author NameAffiliation
Claudine IsaacsGeorgetown University
Denise M WolfUniversity of California San Francisco Department of Laboratory Medicine
Christina YauUniversity of California San Francisco Department of Laboratory Medicine
Christina YauUniversity of California San Francisco Department of Laboratory Medicine
Paul HaluskaMayo Clinic Rochester c/o Merck Corporation
Lajos PusztaiYale University Medical Onciology
Judy C BougheyMayo Clinic Division of Medical Oncology
Rachel L YungUniversity of Washington Seattle Cancer Care Alliance
Rita NandaUniversity of Chicago Section of Hematology/Oncology
Emanuel F PetricoinGeorge Mason University Institute for Advanced Biomedical Research
Emanuel F PetricoinGeorge Mason University Institute for Advanced Biomedical Research
Teresa HelstenUniversity of California San Diego Division of Hematology-Oncology
Melissa Paoloni
Melissa Paoloni
Scott M Berry
William F SymmansMD Anderson Cancer Center
Laura J Van't VeerUniversity of California San Francisco Department of Laboratory Medicine
Donald A Berry
  • 1 - 18

Datasets

Release 1.2